Latest Period
Q1 2026
Security Snapshot
4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share (FDMT) Institutional Ownership
CUSIP: 35104E100
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
150
Shares (Excl. Options)
50,620,192
Price
$9.31
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- FDMT on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 50,620,192
- Total 13F value
- $470,860,518
- Portfolio coverage rank
- 0%
- Share change
- -2,733,549
- Value change
- -$20,210,521
- Number of holders
- 150
- Shares outstanding
- 51,571,939
- SEC-reported price per share
- $8.85
- Insider filing price
- $8.85
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 35104E100.
- 150 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 150 to 150 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $400,364,486 to $470,860,518.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 150 institutions filings for Q1 2026.
Security key
35104E100
Latest holder period
Q1 2026
13F holders
150
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
FDMT full holder history
4D Molecular Therapeutics, Inc. SEC filings
4D Molecular Therapeutics, Inc. company facts
4D Molecular Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 35104E100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
FDMT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 10% | 0% | $52,609,747 | -$4,927,498 | 5,346,519 | -8.6% | BVF PARTNERS L P/IL | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 10% | +28% | $48,852,550 | +$5,691,163 | 5,247,151 | +13% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $50,239,320 | -$5,984,983 | 5,105,622 | -11% | RA Capital Management, L.P. | 31 Mar 2026 |
| GOLDMAN SACHS GROUP INC | 7.5% | -21% | $33,688,569 | -$1,079,634 | 4,286,077 | -3.1% | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2025 |
| Novo Holdings A/S | 6.4% | -5.7% | $28,694,793 | +$3,739,293 | 3,650,737 | +15% | Novo Holdings A/S | 31 Dec 2025 |
| BlackRock, Inc. | 6.6% | -15% | $26,613,959 | -$4,803,137 | 3,062,596 | -15% | BlackRock, Inc. | 30 Sep 2025 |
| STATE STREET CORP | 5.3% | $26,645,490 | 2,707,875 | STATE STREET CORPORATION | 31 Mar 2026 | |||
| Venrock Healthcare Capital Partners III, L.P. | 1.5% | -82% | $2,202,200 | -$7,393,006 | 677,600 | -77% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2025 |
| Deep Track Capital, LP | 1.3% | $1,982,175 | 609,900 | Deep Track Capital, LP | 31 Dec 2024 |
As of 31 Mar 2026, 150 institutional investors reported holding 50,620,192 shares of 4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share (FDMT). This represents 98% of the company’s total 51,571,939 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
86%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% | 5,247,151 | +13% | 0.02% | $48,868,164 |
| RA CAPITAL MANAGEMENT, L.P. | 9.8% | 5,049,779 | -11% | 0.5% | $47,013,442 |
| GOLDMAN SACHS GROUP INC | 8.2% | 4,205,438 | -2.3% | 0.01% | $39,152,628 |
| BlackRock, Inc. | 8% | 4,145,303 | +2% | 0% | $38,592,771 |
| NOVO HOLDINGS A/S | 7.1% | 3,650,737 | 0% | 2.8% | $33,988,361 |
| BVF INC/IL | 5.6% | 2,879,289 | -38% | 0.85% | $26,806,181 |
| STATE STREET CORP | 5.3% | 2,707,875 | +0.71% | 0% | $25,210,316 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 2,195,578 | 0% | 0% | $20,440,831 |
| ARMISTICE CAPITAL, LLC | 3.9% | 2,000,000 | +3.3% | 0.61% | $18,620,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.1% | 1,605,156 | +30% | 0.02% | $14,944,002 |
| FEDERATED HERMES, INC. | 2.8% | 1,432,260 | -11% | 0.02% | $13,334,340 |
| Trails Edge Capital Partners, LP | 2.5% | 1,302,917 | 2.9% | $12,130,157 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 1,065,345 | +5.3% | 0% | $9,921,110 |
| BANK OF AMERICA CORP /DE/ | 1.9% | 974,173 | +17% | 0% | $9,069,551 |
| Evergreen Quality Fund GP, Ltd. | 1.8% | 951,474 | 0% | 0.2% | $8,858,223 |
| DEUTSCHE BANK AG\ | 1.4% | 708,044 | +0.54% | 0% | $6,591,890 |
| RENAISSANCE TECHNOLOGIES LLC | 1.1% | 578,265 | +13% | 0.01% | $5,383,647 |
| Nuveen, LLC | 1.1% | 561,805 | +254% | 0% | $5,230,404 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.1% | 555,829 | 0% | 0% | $5,174,768 |
| DIMENSIONAL FUND ADVISORS LP | 1% | 522,823 | +77% | 0% | $4,862,901 |
| Parkman Healthcare Partners LLC | 1% | 522,577 | +3.8% | 0.5% | $4,865,192 |
| RTW INVESTMENTS, LP | 0.92% | 475,737 | 0% | 0.04% | $4,429,111 |
| JPMORGAN CHASE & CO | 0.81% | 415,655 | +49% | 0% | $3,562,163 |
| Propel Bio Management, LLC | 0.74% | 380,420 | 2.3% | $3,581,151 | |
| MORGAN STANLEY | 0.67% | 345,410 | -49% | 0% | $3,215,767 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
22
Latest
Q1 2026
Rows shown
1-22 of 22
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 50,620,192 | $470,860,518 | -$20,210,521 | $9.31 | 150 |
| 2025 Q4 | 53,383,361 | $400,364,486 | +$104,755,232 | $7.50 | 150 |
| 2025 Q3 | 39,480,388 | $343,063,699 | -$4,201,365 | $8.69 | 129 |
| 2025 Q2 | 40,369,426 | $149,859,289 | -$9,235,482 | $3.71 | 117 |
| 2025 Q1 | 43,058,381 | $139,823,044 | -$22,403,324 | $3.23 | 122 |
| 2024 Q4 | 46,814,824 | $260,642,119 | -$79,332,651 | $5.57 | 140 |
| 2024 Q3 | 57,948,767 | $626,374,639 | -$34,446,524 | $10.81 | 135 |
| 2024 Q2 | 57,307,189 | $1,203,018,791 | +$3,520,347 | $20.99 | 138 |
| 2024 Q1 | 56,228,706 | $1,790,823,856 | +$449,592,828 | $31.86 | 146 |
| 2023 Q4 | 42,433,937 | $859,819,319 | +$24,792,782 | $20.26 | 111 |
| 2023 Q3 | 41,913,779 | $533,559,212 | +$5,221,810 | $12.73 | 110 |
| 2023 Q2 | 41,248,927 | $745,334,512 | +$197,052,931 | $18.07 | 100 |
| 2023 Q1 | 30,404,028 | $522,337,328 | +$34,968,755 | $17.19 | 94 |
| 2022 Q4 | 28,011,571 | $622,110,124 | +$47,681,640 | $22.21 | 97 |
| 2022 Q3 | 26,181,987 | $210,496,945 | +$1,974,268 | $8.04 | 84 |
| 2022 Q2 | 26,027,061 | $181,670,139 | -$2,172,042 | $6.98 | 86 |
| 2022 Q1 | 26,134,053 | $395,189,957 | +$20,420,485 | $15.12 | 76 |
| 2021 Q4 | 24,702,968 | $541,790,297 | +$81,054,878 | $21.94 | 77 |
| 2021 Q3 | 18,711,908 | $504,667,012 | +$57,523,278 | $26.97 | 61 |
| 2021 Q2 | 16,612,608 | $400,026,000 | +$731,531 | $24.08 | 54 |
| 2021 Q1 | 15,384,514 | $664,816,567 | +$34,097,345 | $43.38 | 63 |
| 2020 Q4 | 14,593,004 | $602,432,000 | +$578,482,000 | $41.45 | 51 |